📰 Pharmaceutical Intelligence News
Page 4 - Pharmaceutical Intelligence News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharmaceutical Intelligence. Real-time updates on events, politics, business and more.
October 28, 2023
OTT-166 is under clinical development by OcuTerra Therapeutics and currently in Phase II for Diabetic Macular Edema.
October 28, 2023
DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
October 28, 2023
(IO-102 + IO-103) is under clinical development by IO Biotech and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
October 28, 2023
Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.
October 28, 2023
Litifilimab is under clinical development by Biogen and currently in Phase III for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).
October 28, 2023
BMX-001 is under clinical development by Biomimetix JV and currently in Phase II for Oropharyngeal Cancer.
October 28, 2023
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Extrahepatic Bile Duct Cancer.
October 27, 2023
XTX-202 is under clinical development by Xilio Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.
October 27, 2023
Duvelisib is under clinical development by Secura Bio and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.
October 27, 2023
TC-510 is under clinical development by TCR2 Therapeutics and currently in Phase II for Malignant Pleural Mesothelioma.